However, is the Aussie healthcare stock still in the buy basket after its recent capital gains?
Why Polynovo led the ASX 200 in January
Polynovo is a medical device company that specialises in the treatment of burns through its NovoSorb biodegradable temporising matrix (BTM) technology. The $1.85 billion group’s flagship product is a polymer that integrates with human skin to assist the healing process following severe burns or skin loss.
Polynovo shares jumped early in January after a strong sales update to the market. The Aussie medical group reported its first $2 million month in terms of sales. Unaudited revenue totalled $8.57 million for the half year ended 31 December 2019, up 129% on the previous year.
The growth from Polynovo shares has also been helped by further product testing and development.
The Aussie group’s NovoSorb BTM product has just been applied to its first two UK patients in a big step forward. One patient was treated for necrotising fasciitis in an English NHS hospital, whereas a second patient was treated for a scalp defect.
Shareholders have now seen a 366.70% share price increase since the start of 2019. The group’s market capitalisation has now swelled to $1.85 billion and PolyNovo has entrenched itself in the ASX 200.
Should you buy Polynovo shares?
There’s no doubt the recent share price growth has been impressive from Polynovo. However, you never want to buy into ASX shares that are overvalued.
I think the February earnings season could be a great barometer of where Polynovo shares are headed this year. If we see strong revenue and sales growth, the current $2.80 share price could be good value.
If Polynovo misses the market’s expectations, however, it could be a different story. Investors seem wary of overvalued assets around the world right now, which could see the group’s shares crash lower in February.
Polynovo could be the next CSL Limited (ASX: CSL) or see a similar slump to Nearmap Ltd (ASX: NEA). I’d be waiting to buy Polynovo shares once I’ve got a better view of its growth and earnings profile.
These 3 stocks could be the next big movers in 2020
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Nearmap Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- Why the Xero (ASX:XRO) share price can hit $100 again in 2020 – September 23, 2020 9:35am
- Is the Coles (ASX:COL) share price a buy after renewable energy deal? – September 23, 2020 8:38am
- 3 reasons I like the AGL Energy (ASX:AGL) share price today – September 23, 2020 8:19am